(OTCBB:HDVY) Health Discovery Corp

Turning Pennies into dollars: (OTCBB:HDVY) Health Discovery Corp

Are you a public company looking for exposure?

Contact RealPennies.com - 212-662-2147



For more info: http://www.realpennies.com/otc/hdvy

Health Discovery Corporation Licenses Biomarkers for Noninvasive Urine-Based Prostate Cancer Test to Quest Diagnostics

(OTCBB:HDVY) Health Discovery Corp.

Press Release

Source: Health Discovery Corporation

Health Discovery Corporation Licenses Biomarkers for Noninvasive Urine-Based Prostate Cancer Test to Quest Diagnostics

Thursday February 5, 5:51 pm ET

SAVANNAH, Ga.-Health Discovery Corporation , a molecular diagnostics company, recently announced that it has licensed rights to develop a new urine-based test for clinically significant prostate cancer to Quest Diagnostics Incorporated , the world?s leading provider of diagnostic testing, information and services. Under the terms of the agreement, HDC will receive payments, royalties and additional undisclosed financial considerations.

?We are pleased to work with Quest Diagnostics on the development of an exciting new noninvasive test for clinically significant prostate cancer,? stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. ?Quest Diagnostics performs testing for more than half a million patients each day, serving approximately half of the physicians and hospitals in the United States. It is an ideal clinical laboratory to use our markers for developing a test as an aid in detecting prostate cancer."

Prostate cancer is the second leading cause of cancer mortality among men in the United States behind lung cancer. According to the American Cancer Society, 232,000 new cases of prostate cancer will be diagnosed in the U.S. and an estimated 30,350 deaths will occur from this disease. Furthermore, more than 350,000 patients worldwide are diagnosed with prostate cancer every year. More than 45 million PSA blood tests are currently performed annually worldwide.

About Health Discovery Corporation

Savannah-based Health Discovery Corporation is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as oil exploration, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

This communication contains certain forward-looking statements. These forward-looking statements, which may include, but are not limited to, statements concerning the proposed acquisition, are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Certain of these risks and uncertainties may include, but are not limited to the risks and uncertainties described in the Quest Diagnostics Incorporated 2006 Form 10-K and subsequent filings.

Contact:

Health Discovery Corporation Stephen D. Barnhill, M.D., 912-443-1987 sbarnhill@healthdiscoverycorp.com www.healthdiscoverycorp.com Source: Health Discovery Corporation

Profile for Health Discovery Corp.

Health Discovery Corporation operates as a pattern recognition company that uses mathematical techniques to analyze large amounts of data to uncover patterns. It licenses its support vector machines and fractal genomic modeling technologies to diagnostic and pharmaceutical companies. The company’s discoveries include a subset of genes that separates benign prostatic hyperplasia from prostate cancer and BPH from normal tissue patterns; a genetic biomarker signature, which identifies clinically high grade prostate cancer based on analysis of tissue samples; a set of leukemia genes that separates ALL-T-cell leukemia from ALL-B-cell leukemia; colon cancer-specific biomarkers, which are use... Detailed HDVY Company Description...

LAST $0.07 USD

Find out more about HDVY

Realpennies.com



Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on

http://www.realpennies.com/start.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

RealPennies.com

Phone: 212-662-2147

info [at] realpennies.com